The safety and efficacy of topical retapamulin ointment versus placebo ointment in the treatment of secondarily infected traumatic lesions: A randomized, double-blind superiority study

Advances in Skin and Wound Care

Volumn 26, Issue 3, 2013, Pages 113-121

  Tomayko, John F ^a   Li, Gang ^a   Breton, John J ^a   Scangarella Oman, Nicole ^a   Dalessandro, Marybeth ^a   Martin, Michael ^a,b  

^a GLAXOSMITHKLINE   (United States)

^b Advanced Pediatrics   (United States)

Author keywords

Retapamulin; Secondarily infected traumatic lesions; Topical antibacterial ointment

Indexed keywords

EID: 84876248153     PISSN: 15277941     EISSN: 15388654     Source Type: Journal    
DOI: 10.1097/01.ASW.0000427922.12498.c4     Document Type: Article

References (21)

1. Free A, Roth E, Dalessandro M, et al. Retapamulin ointment twice daily for 5 days vs oral cephalexin twice daily for 10 days for empiric treatment of secondarily infected traumatic lesions of the skin. Skinmed 2006;5:224-32.
2. Food and Drug Administration. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/ Guidances/ucm071185.pdf. Last accessed December 20, 2012.
3. Silverberg N, Block S. Uncomplicated skin and skin structure infectionsin children: diagnosis and current treatment options in the United States. Clin Pediatr (Phila) 2008;47:211-9.
4. Guay DR. Treatment ofbacterial skin and skin structure infections. Expert Opin Pharmacother 2003;4:1259-75.
5. Howden BP, Grayson ML. Dumb and dumberVthe potential waste of a useful antistaph-ylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis 2006;42:394-400.
6. Katz KC, McGeer AJ, Duncan CL, et al. Emergence of macrolide resistance in throat culture isolates of group a streptococci in Ontario, Canada, in 2001. Antimicrob Agents Chemother 2003;47:2370-2.
7. Deshpande LM, Fix AM, Pfaller MA, et al. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diagn Microbiol Infect Dis 2002;42:283-90.
8. Rittenhouse S, Biswas S, Broskey J, et al. Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrob Agents Chemother 2006;50:3882-5.
9. Scangarella-Oman NE, Shawar RM, Bouchillon S, et al. Microbiological profile of anew topical antibacterial: retapamulin ointment 1%. Expert Rev Anti Infect Ther 2009;7:269-79.
10. Gisby J, Bryant J. Efficacy of a new cream formulation of mupirocin: comparison with oral and topical agents in experimental skin infections. Antimicrob Agents Chemother 2000;44:255-60.
11. Koning S, van der Wouden JC, Chosidow O, et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. Br J Dermatol 2008;158:1077-82.
12. Oranje AP, Chosidow O, Sacchidanand S, et al. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Dermatology 2007;215:331-40.
13. Breneman DL. Use of mupirocin ointment in the treatment of secondarily infected dermatoses. J Am Acad Dermatol 1990;22:886-92.
14. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement. CLSI Document M100-S17 [ISBN 1-56238-625-5]. Wayne, PA: CLSI; 2007.
15. Johnsson D, Molling P, Stralin K, et al. Detection of Panton-Valentine leukocidin gene in Staph-ylococcus aureus by LightCycler PCR: clinical and epidemiological aspects. Clin Microbiol Infect 2004;10:884-9.
16. Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999;29:1128-32.
17. McDougal LK, Steward CD, Killgore GE, et al. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 2003;41:5113-20.
18. Wolter DJ, Tenover FC, Goering RV. Allelic variationingenes encoding Panton-Valentine leukocidin from community-associated Staphylococcus aureus. Clin Microbiol Infect 2007;13:827-30.
19. Goering RV. Pulsed-field gel electrophoresis. Molecular Microbiology: Diagnostic Principles and Practice. Washington, DC: ASM Press; 2004:185-96.
20. Agresti A, Hartzel J. Strategies for comparing treatments on a binary response with multi-centre data. Stat Med 2000;19:1115-39.
21. Parish LC, Jorizzo JL, Breton JJ, et al. Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial. J Am Acad Dermatol 2006;55:1003-13.